Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology announced that investigator-initiated Phase 1 data for LYMPHIR in combination with pembrolizumab has been selected for poster presentation at the 2026 ASCO Annual Meeting. The study in relapsed/refractory gynecologic malignancies reported a 24% objective response rate and a 21.1-month average duration of response in responders, with a favorable safety profile.
Key figures
- Drug Name
- LYMPHIR (denileukin diftitox-cxdl)
- Phase Of Trial
- Phase 1
- Duration of response
- 21.1 months
- Market size estimate
- $400 million
- Objective response rate
- 24%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.